Cargando…

Editorial: Metabolic reprogramming for acquiring therapeutic resistance in glioblastoma

Detalles Bibliográficos
Autor principal:	Hsu, Tsung-I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382683/ https://www.ncbi.nlm.nih.gov/pubmed/37519794 http://dx.doi.org/10.3389/fonc.2023.1220063

Ejemplares similares

Editorial: Metabolic reprogramming in breast cancer
por: Scatena, Cristian, et al.
Publicado: (2022)

Editorial: Therapy resistance in tumor microenvironment: metabolic reprogramming and purinergic signaling
por: Zanoni, Michele, et al.
Publicado: (2023)

Editorial: Hallmark of cancer: Reprogramming of cellular metabolism
por: Kaur, Baljinder, et al.
Publicado: (2023)

Editorial: Cell Stress, Metabolic Reprogramming, and Cancer
por: Giannattasio, Sergio, et al.
Publicado: (2018)

Editorial: Exploring Cancer Metabolic Reprogramming through Molecular Imaging
por: Podo, Franca, et al.
Publicado: (2017)

Editorial: Primary and acquired resistance in lung cancer
por: Bruno, Rossella, et al.
Publicado: (2023)

Editorial: Proteomic and metabolic reprogramming in myeloma cells within the tumor microenvironment
por: Milan, Enrico, et al.
Publicado: (2023)

Metabolic Reprogramming During Multidrug Resistance in Leukemias
por: Vidal, Raphael Silveira, et al.
Publicado: (2018)

Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma
por: Nguyen, Trang T. T., et al.
Publicado: (2022)

Corrigendum: Metabolic Reprogramming During Multidrug Resistance in Leukemias
por: Vidal, Raphael Silveira, et al.
Publicado: (2018)

Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy
por: Giacomini, Isabella, et al.
Publicado: (2021)

Editorial: Metabolism As a Therapeutic Target
por: Columbano, Amedeo, et al.
Publicado: (2017)

Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming
por: Adeshakin, Funmilayo O., et al.
Publicado: (2021)

Relationship between metabolic reprogramming and drug resistance in breast cancer
por: Lv, Linlin, et al.
Publicado: (2022)

Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies
por: Ricci, Jean-Ehrland, et al.
Publicado: (2018)

Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies
por: Xu, Ruiyuan, et al.
Publicado: (2020)

The Role and Therapeutic Perspectives of Sirtuin 3 in Cancer Metabolism Reprogramming, Metastasis, and Chemoresistance
por: Zhao, QingYi, et al.
Publicado: (2022)

Assessing Current Therapeutic Approaches to Decode Potential Resistance Mechanisms in Glioblastomas
por: Sze, Chun-I, et al.
Publicado: (2013)

Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer
por: Yan, Jinbowen, et al.
Publicado: (2023)

Editorial: Oncogenic RAS-Dependent Reprogramming of Cellular Plasticity
por: Konstantinidou, Georgia, et al.
Publicado: (2020)

Metabolic Reprogramming in Thyroid Carcinoma
por: Coelho, Raquel Guimaraes, et al.
Publicado: (2018)

Editorial: Epigenetics and cellular plasticity in glioblastoma
por: Lo, Hui-Wen, et al.
Publicado: (2023)

STAT3-Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug Resistance
por: Poli, Valeria, et al.
Publicado: (2015)

Editorial: Cancer cell reprogramming: Impact on carcinogenesis and cancer progression
por: Zhao, Yue, et al.
Publicado: (2023)

Editorial: Tumor Cell Metabolism and Autophagy as Therapeutic Targets
por: Jacobo-Herrera, Nadia, et al.
Publicado: (2020)

Serine-associated one-carbon metabolic reprogramming: a new anti-cancer therapeutic strategy
por: Zhang, Jing, et al.
Publicado: (2023)

Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities
por: Kao, Tzu-Jen, et al.
Publicado: (2023)

Macrophages and Metabolic Reprograming in the Tumor Microenvironment
por: Liu, Jin, et al.
Publicado: (2022)

The Role of 2-Oxoglutarate Dependent Dioxygenases in Gliomas and Glioblastomas: A Review of Epigenetic Reprogramming and Hypoxic Response
por: Crake, Rebekah L. I., et al.
Publicado: (2021)

CD147 Mediates 5-Fluorouracil Resistance in Colorectal Cancer by Reprogramming Glycolipid Metabolism
por: Dong, Shuohui, et al.
Publicado: (2022)

Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation
por: Tsai, Yu-Ting, et al.
Publicado: (2022)

Radiation-Induced Changes in Tumor Vessels and Microenvironment Contribute to Therapeutic Resistance in Glioblastoma
por: Seo, Yun-Soo, et al.
Publicado: (2019)

Lipid metabolism reprogramming in head and neck cancer
por: Liang, Jinfeng, et al.
Publicado: (2023)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Editorial: Targeted Therapies for Glioblastoma: A Critical Appraisal
por: Gupta, Shiv K., et al.
Publicado: (2019)

Editorial: The molecular mechanisms of metastasis and therapeutic resistance in breast cancer
por: Liang, Yuanke, et al.
Publicado: (2023)

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
por: Yoshimoto, Koji, et al.
Publicado: (2012)

Lipid droplets and ferroptosis as new players in brain cancer glioblastoma progression and therapeutic resistance
por: Bezawork-Geleta, Ayenachew, et al.
Publicado: (2022)

Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma
por: Won, Woong-Jai, et al.
Publicado: (2019)

Orchestral role of lipid metabolic reprogramming in T-cell malignancy
por: Mehta, Arundhati, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2ks5ptrsc92ha3s9ebccdb21v3